GO:0042043 neurexin family protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042043 (neurexin family protein binding) is a molecular function describing the selective binding of proteins to neurexins, which are presynaptic cell-surface molecules.
• Neurexins are encoded by NRXN1, NRXN2 and NRXN3 and act as synaptic organizers through interactions with neuroligins, CASK, and other ligands.
• Heterozygous deletions and rare variants in NRXN1 are associated with neurodevelopmental disorders including autism spectrum disorder and schizophrenia.
• The neurexin-neuroligin interaction is a key model for synapse formation and has been linked to neuropsychiatric disease mechanisms.
• Autoantibodies against CASPR2, a neurexin-binding protein, can alter neuronal excitability and contribute to neuropathic pain.
• Patient-derived variants in CASK PDZ domain affect ligand binding, illustrating the functional impact of mutations in neurexin-associated complexes.
Description
Neurexin family protein binding (GO:0042043) is a molecular function that describes the binding of a protein to a neurexin, a synaptic cell surface protein related to latrotoxin receptor, laminin and agrin. Neurexins act as cell recognition molecules at nerve terminals and are central to synaptic organization and function. This GO term captures the interactions that mediate these roles, including binding to neuroligins, CASK, and other synaptic proteins. Understanding this function is critical for researchers studying synapse formation, neural circuit development, and neuropsychiatric disorders. The term is particularly relevant because neurexins are among the most extensively studied synaptic cell adhesion molecules, and their interactions are implicated in a wide range of neurodevelopmental and psychiatric conditions. As such, GO:0042043 provides a framework for investigating how molecular interactions at the synapse contribute to both normal brain function and disease.
neurexin family protein binding At A Glance
| GO ID | GO:0042043 |
|---|---|
| GO term | neurexin family protein binding |
| Ontology | molecular_function |
| Synonym | neuroligin |
| Definition | Binding to a neurexin, a synaptic cell surface protein related to latrotoxin receptor, laminin and agrin. Neurexins act as cell recognition molecules at nerve terminals. |
| Major function | Mediates protein-protein interactions at the synapse, particularly with neuroligins and CASK, to organize synaptic structure and signaling. |
| Related genes | NRXN1, NRXN2, NRXN3, NLGN1, NLGN2, NLGN3, NLGN4X, CASK, CNTNAP2. |
| Disease relevance | Mutations in neurexins and their binding partners are linked to autism spectrum disorder, schizophrenia, and other neurodevelopmental disorders. |
What Is GO:0042043?
In simple terms, GO:0042043 describes the ability of a protein to physically bind to a neurexin. Neurexins are cell surface proteins found on nerve terminals that help cells recognize and connect with each other. The definition from QuickGO states: Binding to a neurexin, a synaptic cell surface protein related to latrotoxin receptor, laminin and agrin. Neurexins act as cell recognition molecules at nerve terminals. This function is a molecular activity, meaning it is the binding event itself, not a larger process. It is a key mechanism by which neurexins communicate with other proteins to organize synapses.
Why Is neurexin family protein binding Important in Cell Biology?
Neurexin family protein binding is fundamental to synaptic function because it underlies the physical connections that allow neurons to communicate. Neurexins are presynaptic adhesion molecules that bind to postsynaptic partners such as neuroligins, forming trans-synaptic bridges that are essential for synapse formation, maturation, and plasticity. Disruption of these interactions has been repeatedly associated with neurodevelopmental and psychiatric disorders, including autism spectrum disorder and schizophrenia. Moreover, neurexin-binding proteins like CASK and CASPR2 are implicated in neurological conditions ranging from neuropathic pain to developmental syndromes. Therefore, studying this molecular function provides mechanistic insight into brain development and disease, and offers potential targets for therapeutic intervention.
• Neurexin family protein binding is essential for synapse formation and function, as neurexins act as presynaptic organizers.
• It mediates trans-synaptic adhesion through interactions with neuroligins, which are critical for synaptic signaling.
• Heterozygous NRXN1 deletions are associated with autism spectrum disorder, schizophrenia, and other neurodevelopmental phenotypes.
• Rare variants in NRXN and NLGN gene families have been linked to neurodevelopmental disorders.
• Autoantibodies against CASPR2, a neurexin-binding protein, can cause neuronal hyperexcitability and neuropathic pain.
• Mutations in CASK, a neurexin-interacting protein, affect ligand binding and are linked to brain malformations.
• The term is a target for research into synaptic mechanisms of disease and potential therapeutic strategies.
• Understanding neurexin binding specificity can inform studies of neural circuit assembly and plasticity.
• It provides a molecular entry point for investigating gene-environment interactions in neuropsychiatric disorders.
• Neurexin interactions are conserved across species, making them amenable to model organism studies.
Molecular Mechanism of neurexin family protein binding
Neurexin structure and ligand-binding domains
In simple terms: Neurexins are like molecular Velcro on the surface of nerve cells, with specific patches that grab onto partner proteins.
Neurexins are type I membrane proteins with an extracellular domain containing multiple laminin/neurexin/sex hormone-binding globulin (LNS) domains and epidermal growth factor (EGF)-like repeats. These domains mediate binding to a variety of ligands, including neuroligins, which are postsynaptic cell adhesion molecules. The extracellular region is subject to extensive alternative splicing, generating thousands of isoforms that differ in their binding properties. This splicing is thought to provide specificity in synaptic connectivity.
Interaction with neuroligins
In simple terms: Neurexins on one side of the synapse shake hands with neuroligins on the other side, forming a connection that holds the synapse together.
The binding of neurexins to neuroligins is one of the best-characterized trans-synaptic interactions. Neuroligins are postsynaptic membrane proteins that bind to the LNS domain of neurexins in a calcium-dependent manner. This interaction is thought to trigger bidirectional signaling that leads to synapse formation and maturation. Mutations in neuroligin genes (NLGN1, NLGN2, NLGN3, NLGN4X) have been associated with autism spectrum disorders, underscoring the importance of this binding event.
Binding to CASK and intracellular partners
In simple terms: Inside the cell, neurexins can also bind to proteins like CASK, which help anchor them and connect them to the cytoskeleton.
Neurexins interact with intracellular proteins such as CASK (calcium/calmodulin-dependent serine protein kinase) through their cytoplasmic C-terminal PDZ-binding motif. CASK is a multidomain scaffolding protein that links neurexins to the actin cytoskeleton and to signaling pathways. Patient-derived variants in the CASK PDZ domain can disrupt ligand binding, highlighting the functional importance of this interaction. This binding is critical for synaptic stability and function.
Regulation by alternative splicing
In simple terms: Neurexins can be cut and pasted in different ways to create many versions, each with different binding preferences.
Alternative splicing of neurexin mRNAs generates extensive isoform diversity, particularly in the LNS domains. Splicing at splice site 4 (SS4) in NRXN1, for example, affects binding to neuroligins and other ligands. This splicing is regulated in a cell-type-specific and activity-dependent manner, allowing fine-tuning of synaptic interactions. The diversity of neurexin isoforms is thought to contribute to the specificity of neural circuits.
Calcium dependence and affinity
In simple terms: The handshake between neurexins and their partners often requires calcium, which acts like a helper that strengthens the grip.
Many neurexin-ligand interactions, including binding to neuroligins, are calcium-dependent. Calcium ions are thought to stabilize the binding interface, increasing affinity. This dependence allows synaptic activity, which changes local calcium concentrations, to modulate adhesion. The affinity of neurexin binding can vary widely depending on the ligand and splice isoform.
Key Genes Involved in GO:0042043 neurexin family protein binding
The following genes encode proteins that either are neurexins or bind to neurexins, thereby participating in GO:0042043.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NRXN1 | Encodes neurexin-1, a presynaptic cell adhesion molecule | Heterozygous deletions and variants are linked to autism and schizophrenia. |
| NRXN2 | Encodes neurexin-2, a presynaptic cell adhesion molecule | Rare variants have been found in neurodevelopmental disorders. |
| NRXN3 | Encodes neurexin-3, a presynaptic cell adhesion molecule | Associated with neuropsychiatric phenotypes. |
| NLGN1 | Postsynaptic neuroligin that binds neurexins | Synaptic organizer; variants linked to autism. |
| NLGN2 | Postsynaptic neuroligin, binds neurexins | Involved in inhibitory synapse formation. |
| NLGN3 | Postsynaptic neuroligin, binds neurexins | Mutations associated with autism spectrum disorder. |
| NLGN4X | Postsynaptic neuroligin, binds neurexins | Mutations linked to autism and intellectual disability. |
| CASK | Intracellular scaffolding protein that binds neurexins | PDZ domain variants affect ligand binding and cause brain malformations. |
| CNTNAP2 | Neurexin family member (CASPR2), binds to contactin | Autoantibodies against CASPR2 cause neuropathic pain. |
| GABRA1 | GABA receptor subunit, indirectly linked to neurexin signaling | May be affected by neurexin-neuroligin complexes. |
| DLG4 | Postsynaptic scaffolding protein (PSD-95), interacts with neuroligins | Modulates neurexin-neuroligin signaling. |
| SHANK3 | Postsynaptic scaffold, part of neuroligin complex | Implicated in autism and synaptic dysfunction. |
| GRIN2B | NMDA receptor subunit, influenced by neurexin signaling | Linked to neurodevelopmental disorders. |
| NRXN1α | Major isoform of neurexin-1 | Studied for its role in synaptic specificity. |
| NRXN1β | Shorter isoform of neurexin-1 | Less studied but may have distinct binding properties. |
| NLGN4Y | Y-linked neuroligin, binds neurexins | Associated with autism in males. |
| PTPRD | Protein tyrosine phosphatase receptor, interacts with neurexins | Candidate risk gene for neurodevelopmental disorders. |
How Is neurexin family protein binding Regulated?
The function of neurexin family protein binding is regulated at multiple levels. Alternative splicing of neurexin mRNAs generates isoforms with different binding affinities for ligands such as neuroligins. This splicing is controlled by cell-type-specific RNA-binding proteins and can be modulated by neuronal activity. Additionally, post-translational modifications, including glycosylation, may influence neurexin stability and interactions. Calcium availability also regulates binding, as many neurexin-ligand interactions are calcium-dependent. Finally, the expression of neurexin genes is developmentally regulated, with peak expression during synaptogenesis.
neurexin family protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NRXN1 | Autism spectrum disorder, schizophrenia | NRXN1 knockout and point-mutation iPSC-derived neurons. |
| NLGN3 | Autism spectrum disorder | NLGN3 knock-in mice or human neurons. |
| CASK | Brain malformations, intellectual disability | CASK PDZ domain point mutations in cell models. |
| CNTNAP2 | Neuropathic pain, autoimmune encephalitis | CASPR2 autoantibody exposure in cultured neurons. |
| NRXN2 | Neurodevelopmental disorders | NRXN2 knockout models. |
Neurodevelopmental disorders
Disruption of neurexin family protein binding is strongly associated with neurodevelopmental disorders. Heterozygous deletions of NRXN1 are linked to autism spectrum disorder, developmental delay, and schizophrenia. A study of 34 families with NRXN1 deletions found variable phenotypic expressivity, including autism, intellectual disability, and behavioral problems. Another study highlighted the phenotypic complexities of rare heterozygous neurexin-1 deletions, showing diverse neurodevelopmental outcomes. Rare variants in NRXN and NLGN gene families have also been associated with neurodevelopmental disorders. These findings underscore the critical role of neurexin binding in brain development.
Neuropsychiatric disorders
Neurexins and their binding partners have been implicated in neuropsychiatric disorders beyond autism. Neurexin dysfunction has been linked to schizophrenia and other psychiatric conditions. The neurexin-neuroligin interaction is thought to contribute to the pathophysiology of these disorders through effects on synaptic signaling and network activity. Genetic studies have identified rare variants in neurexin genes in patients with schizophrenia, further supporting a role for this molecular function.
Neuropathic pain and autoimmune conditions
Autoantibodies against CASPR2, a neurexin family protein, have been implicated in neuropathic pain. A study showed that CASPR2 autoantibody IgG subclasses drive neuronal hyperexcitability, contributing to pain mechanisms. This highlights how disruption of neurexin-related interactions can lead to neurological symptoms beyond developmental disorders. The binding of CASPR2 to its partners is part of the broader neurexin family protein binding function, and its perturbation can have significant clinical consequences.
From neurexin family protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NRXN1 affect synapse formation? | NRXN1 knockout human iPSC-derived neurons. |
| How do patient variants in NRXN1 alter binding? | Point-mutation knock-in of specific variants. |
| Can we tag endogenous neurexins to study localization? | Knock-in of fluorescent tags at NRXN1 locus. |
| What is the effect of neuroligin overexpression? | Overexpression of NLGN3 in cultured neurons. |
| Does CASK PDZ mutation disrupt neurexin binding? | Point mutation in CASK PDZ domain. |
| Can we screen for modifiers of neurexin binding? | CRISPR library screening in neuronal cells. |
How to Study the neurexin family protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Protein-protein interactions | Detect neurexin-neuroligin complexes. |
| Surface plasmon resonance | Binding affinity and kinetics | Quantify calcium dependence of neurexin binding. |
| CRISPR knockout | Loss-of-function effects | Study NRXN1 deletion in neurons. |
| RNA sequencing | Transcriptomic changes | Identify downstream pathways affected by neurexin mutations. |
| Electrophysiology | Synaptic transmission | Measure effects of neurexin binding on neuronal activity. |
| Super-resolution imaging | Subcellular localization | Visualize neurexin at synapses. |
| Chromosomal microarray | Copy number variants | Detect NRXN1 deletions in patients. |
| Proteomics | Protein interaction networks | Identify novel neurexin-binding partners. |
Biochemical binding assays
To study neurexin family protein binding, researchers use in vitro binding assays such as co-immunoprecipitation, pull-down assays, and surface plasmon resonance (SPR). These methods allow measurement of binding affinity and specificity between neurexins and their ligands. For example, SPR can quantify the calcium dependence of neurexin-neuroligin interactions.
Cell-based assays
Cell-based assays, including co-culture of neurexin-expressing and neuroligin-expressing cells, can assess synapse formation and binding-dependent signaling. Artificial synapse formation assays using beads coated with neurexin fragments are also used to study postsynaptic differentiation. These methods provide functional readouts of neurexin binding.
Genetic and genomic approaches
CRISPR-Cas9 genome editing enables the creation of knockout, point-mutation, and knock-in models to study the consequences of altered neurexin binding. RNA sequencing and proteomics can reveal downstream effects on gene expression and protein networks. Chromosomal microarray analysis has been used to identify NRXN1 deletions in patients.
Imaging and electrophysiology
Advanced imaging techniques, such as super-resolution microscopy and live-cell imaging, allow visualization of neurexin localization and dynamics at synapses. Electrophysiology, including patch-clamp recordings, measures synaptic transmission and plasticity in neurons with manipulated neurexin binding. These approaches link molecular interactions to circuit function.
How CRISPR Can Be Used to Study GO:0042043 neurexin family protein binding
Knockout
CRISPR knockout of NRXN1, NRXN2, or NRXN3 in human iPSC-derived neurons or cell lines can model loss of neurexin function. Such models have been used to study synaptic deficits and neurodevelopmental phenotypes. Knockout of NLGN genes can similarly reveal the importance of neurexin-neuroligin binding.
Point Mutation
Introducing patient-specific point mutations into NRXN1 or CASK using CRISPR base editing or homology-directed repair allows precise investigation of how single amino acid changes affect neurexin binding. For example, mutations in the CASK PDZ domain that disrupt ligand binding have been modeled to understand their functional impact.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at endogenous NRXN1 loci enables real-time tracking of neurexin localization and interactions. Knock-in of disease-associated variants can also be used to create isogenic models for comparing binding properties.
Overexpression
Overexpression of neurexins or their binding partners (e.g., NLGN3) in cultured neurons or cell lines can be achieved via lentiviral or CRISPR activation (CRISPRa) systems. This approach is useful for studying gain-of-function effects on synapse formation and function.
How EDITGENE Supports neurexin family protein binding Research
Researchers studying neurexin family protein binding-related genes often need to determine whether a candidate gene is causally involved in synaptic function or disease. This requires precise genetic models that can isolate the effects of specific mutations or expression changes. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such investigations.
Contact EDITGENE today to design your custom CRISPR model for neurexin family protein binding research.
Frequently Asked Questions About neurexin family protein binding
What is GO:0042043?
GO:0042043 is the Gene Ontology term for neurexin family protein binding, a molecular function describing the binding of a protein to a neurexin.
What genes are involved in neurexin family protein binding?
Key genes include NRXN1, NRXN2, NRXN3, NLGN1, NLGN2, NLGN3, NLGN4X, CASK, and CNTNAP2.
What diseases are associated with neurexin family protein binding?
Mutations in neurexins and their binding partners are linked to autism spectrum disorder, schizophrenia, and neurodevelopmental disorders.
How is neurexin family protein binding studied?
It is studied using biochemical binding assays, cell-based assays, CRISPR genome editing, imaging, and electrophysiology.
What is the role of neuroligins in neurexin binding?
Neuroligins are postsynaptic proteins that bind neurexins to form trans-synaptic bridges essential for synapse formation.
Can CRISPR be used to study neurexin binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to investigate neurexin function and binding.
What is the clinical significance of NRXN1 deletions?
Heterozygous NRXN1 deletions are associated with variable neurodevelopmental phenotypes, including autism and intellectual disability.
How does alternative splicing affect neurexin binding?
Alternative splicing generates neurexin isoforms with different binding affinities for ligands such as neuroligins.
What is the link between CASK and neurexin binding?
CASK binds to the cytoplasmic tail of neurexins, and mutations in its PDZ domain can disrupt this interaction.
Are there autoantibodies against neurexin-binding proteins?
Yes, autoantibodies against CASPR2, a neurexin family protein, have been implicated in neuropathic pain.
Conclusion
Neurexin family protein binding (GO:0042043) is a fundamental molecular function that underlies synaptic organization and neural circuit formation. Its importance is underscored by the strong genetic evidence linking neurexin and neuroligin mutations to neurodevelopmental and psychiatric disorders. Continued research using advanced CRISPR models and biochemical assays will further elucidate the mechanisms and therapeutic potential of targeting these interactions. EDITGENE provides the tools and expertise to support such investigations, from custom knockout and knock-in models to high-throughput screening.
References
- 1. Reissner C et al.. 2013. Neurexins.. Genome Biol 14(9):213 PMID: 24083347
- 2. Al Shehhi M et al.. 2019. NRXN1 deletion syndrome; phenotypic and penetrance data from 34 families.. Eur J Med Genet 62(3):204-209 PMID: 30031152
- 3. Fernando MB et al.. 2025. Phenotypic complexities of rare heterozygous neurexin-1 deletions.. Nature 642(8068):710-720 PMID: 40205044
- 4. Kasem E et al.. 2018. Neurexins and neuropsychiatric disorders.. Neurosci Res 127:53-60 PMID: 29221905
- 5. Habib M et al.. 2025. Neuropathic Pain and Distinct CASPR2 Autoantibody IgG Subclasses Drive Neuronal Hyperexcitability.. Neurol Neuroimmunol Neuroinflamm 12(4):e200423 PMID: 40561371
- 6. Roberts JL et al.. 2014. Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders or learning disability presenting for genetic services.. Gene 535(1):70-8 PMID: 24188901
- 7. Gerik-Celebi HB et al.. 2024. Rare heterozygous genetic variants of NRXN and NLGN gene families involved in synaptic function and their association with neurodevelopmental disorders.. Dev Neurobiol 84(3):158-168 PMID: 38739110
- 8. Tibbe D et al.. 2025. Patient-Derived Variants Define Constraints for Ligand Binding at the PDZ Domain of CASK.. J Neurochem 169(12):e70303 PMID: 41321276
